Table 1 Baseline characteristics of the study population
t2DM (n = 30) | non-t2DM (n = 30) | p-value | |
|---|---|---|---|
Age (y–o) | 56.7 (49.2, 64.2) | 42.2 (30.7, 50.5) | 0.01 |
Age > 65 years | 6 (20.0%) | 2 (6.7%) | 0.01 |
Male | 15 (50.0%) | 10 (33.3%) | 0.1 |
Weight (kg) | 67.8 (54.3, 77.1) | 70.5 (58.7, 84.2) | 0.59 |
Height (cm) | 158.0 (150.0, 168.2) | 161.6 (153.0, 168.5) | 0.37 |
BMI (kg/m2) | 26.7 (23.7, 28.5) | 26.7 (23.3, 29.0) | 0.9 |
Comorbidities | |||
Hypertension | 0 (0) | 2 (6.7%) | 0.39 |
Dyslipidemia | 11 (36.7%) | 16 (53.3%) | 0.20 |
Blood chemistry | |||
Cholesterol (mg/dL) | 175.8 (150.5, 204.7) | 175.1 (141.7, 203.7) | 0.9 |
Triglycerides (mg/dL) | 146.9 (94.0, 153.0) | 147.2 (94.0, 189.0) | 0.9 |
HbA1c (%) | 8.3 (6.4, 9.6) | N. A | 0.01 |
Smoking history | 13 (43.3%) | 10 (33.3%) | 0.41 |
Time from t2DM onset (years) | 10.9 (5.0, 15.0) | N. A | 0.01 |
T2DM related vascular complications | |||
None | 23 (76.7%) | N. A | 0.01 |
Retinopathy | 1 (3.3%) | ||
Neuropathy | 2 (6.7%) | ||
Combined | 4 (13.3%) | ||
T2DM drug therapy | |||
MET | 3 (10.0%) | N. A | 0.01 |
Insulin | 2 (6.7%) | ||
Insulin + MET | 9 (30.0%) | ||
Insulin + MET + other* | 7 (23.3%) | ||
MET + other* | 7 (23.3%) | ||
Insulin + other* | 2 (6.7%) | ||
Renal function | |||
Serum creatinine | 0.76 (0.67, 0.83) | 0.75 (0.67, 0.81) | 0.76 |
GFR (mL/min) | 99.3 (74.6, 120.1) | 118.06 (84.75, 146.65) | 0.06 |
Transferrinuria (mg/ml) | 14.4 (0.7, 28.8) | 18.7 (12.7, 25.3) | 0.04 |
Transferrinemia (mg/ml) | 2.7 (0.2, 17.0) | 2.3 (0.3, 2.2) | 0.27 |
Transferrinuria/transferrinemia Index | 74.2 (0.0, 126.4) | 49.5 (5.1, 68.7) | 0.01 |
Endothelial dysfunction and atherogenesis | |||
FMD value (%) | 9.9 (3.2, 16.0) | 19.5 (10.9, 26.2) | 0.01 |
CIMT value (mm) | 1.19 (0.9, 1.3) | 0.66 (0.5, 0.8) | 0.01 |
ABI value | 1.25 (1.14, 1.35) | 1.19 (1.12, 1.26) | 0.14 |